PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Symporia Bioscience

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Loss of Legal and Regulatory Protection on Major Brand Drugs Creates Multiple Opportunities for Generics According to Symporia Bioscience - Generic drugs are having a disruptive influence on the drug industry and the way brand drug developers patent and market their products - Symporia.com
Loss of Legal and Regulatory Protection on Major Brand Drugs Creates Multiple Opportunities for Generics According to Symporia Bioscience

 

NewswireToday - /newswire/ - Amherst, NH, United States, 2013/12/02 - Generic drugs are having a disruptive influence on the drug industry and the way brand drug developers patent and market their products - Symporia.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Often, the accidental timing of expiring patent and exclusivity protection for branded drugs in a particular therapeutic segment occur within a relatively compressed time period. The result can be a concentrated and accelerated transformation of the segment from one dominated by high-priced brand drugs to one populated by numerous generic products and suppliers, at least until the next-generation brand drug with improved outcomes and lower side effects is introduced into the market.

Pulmonary arterial hypertension (PAH) is continuous high blood pressure in the pulmonary artery. The average blood pressure in a normal pulmonary artery is about 14 mm/Hg when the person is resting. In PAH, the average is usually greater than 25 mm/Hg. There are two types of PAH. Primary pulmonary arterial hypertension (PPAH) is inherited or occurs for no known reason. Secondary pulmonary arterial hypertension (SPAH) either is caused by or occurs because of another condition. The conditions include chronic heart or lung disease, blood clots in the lungs, or a disease like scleroderma. About 300 new cases of PPAH are diagnosed in the United States each year. SPAH is much more common.

Treatments for PAH consist of FDA approved drugs delivered orally, by inhalation and by injection. Oral solid dosage (OSD) forms had global sales of slightly less than $3 billion in 2012. This total is comprised of four branded OSD drugs. Of these four, Revatio lost patent protection in late 2012. Tracleer, the leading drug in this class in terms of revenue, will lose patent protection in 2015. Letairis, the newest of the OSD drugs indicated for PAH, will lose FDA exclusivity and the majority of its patent protection by 2015.

The flurry of activity surrounding Pfizer’s Revatio is a harbinger of things to come. Five generics have entered the market in the past eighteen months. As a result of this generic competition, Revatio revenue will decline 75% this year. Generic activity will further accelerate with the loss of patent protection for Tracleer, the market segment leader, in late 2015. Tracleer’s revenue exceeded $1.6 billion in 2012. Letairis, the third brand of oral solid dosage drug for treating PAH, will loss a significant level of competitive protection by 2015 when several patents are set to expire. A successful P (iv) challenge could and likely will result in a first-to-file generic version of Letairis being launched by 2016.

The net result of generic activity in the PAH therapeutic drug segment will be a drop in total global revenue for all solid dosage forms of 50% from 2014 to 2018, even while total prescriptions will rise by 4.5% per year.

About Symporia Bioscience

Symporia Bioscience (symporia.com) analyzes generic drug markets, publishing generic drug First-to-File Opportunity Assessments, which are designed to allow industry managers to understand and evaluate the market potential for selected branded drugs from the viewpoint of creating and refining FDA ANDA regulatory filings in pursuit of first-filer generic drug applications. By applying predictive analytics to known drug market data, generic drug first-to-file opportunity assessments provide a unique view into the evolving generics drug sector. The publications represent detailed assessments of selected branded drugs in several important areas. The resulting conclusions are contained in written reports that are structured to provide timely insight to market participants.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Symporia Bioscience

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Loss of Legal and Regulatory Protection on Major Brand Drugs Creates Multiple Opportunities for Generics According to Symporia Bioscience

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Paul Brooks - Symporia.com 
603-341-3052 prbrooks[.]symporia.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Symporia Bioscience securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Symporia Bioscience / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)